Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?

Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	TTM Q1 '26	TTM Q4 '25	TTM Q3 '25	TTM Q2 '25	TTM Q1 '25
Total revenue	$535.08M+18.5%	$451.36M+23.3%	$366.1M+23.9%	$295.52M+26.5%	$233.67M+27.7%
Total cost of revenue	——	——	——	——	——
Gross profit	——	——	——	——	——
Research and development	$72.26M+12.3%	$64.32M+1.8%	$63.16M+7.0%	$59M+5.9%	$55.73M+4.4%
Selling, general and administrative	$478.76M+12.0%	$427.32M+16.9%	$365.67M+16.1%	$314.95M+16.3%	$270.73M+14.1%
Total costs & expenses	$585.89M+12.2%	$522.33M+15.2%	$453.51M+15.2%	$393.57M+14.8%	$342.84M+13.0%
Operating income	-$50.81M+28.4%	-$70.97M+18.8%	-$87.41M+10.8%	-$98.05M+10.2%	-$109.17M+9.5%
Operating margin	-9.5%+6.2pp	-15.7%+8.2pp	-23.9%+9.3pp	-33.2%+13.5pp	-46.7%+19.2pp
Interest expense	$8.85M-1.0%	$8.94M-1.1%	$9.03M-1.9%	$9.21M+1.4%	$9.08M+15.7%
Interest income	$16.02M+1.7%	$15.75M+2.0%	$15.44M0.0%	$15.45M+0.6%	$15.35M+2.2%
Other income (expense), net	$6.96M+5.2%	$6.61M+5.7%	$6.26M+3.3%	$6.05M+43.4%	$4.22M-15.8%
Income before income taxes	——	-$64.36M+16.6%	-$77.16M+14.2%	-$89.96M+12.5%	-$102.76M+11.1%
Income tax expense	——	——	——	——	$0—
Net income	-$48.27M+27.3%	-$66.42M+18.2%	-$81.16M+11.8%	-$91.99M+12.3%	-$104.94M+9.2%
Net margin	-9%+5.7pp	-14.7%+7.5pp	-22.2%+9.0pp	-31.1%+13.8pp	-44.9%+18.3pp
Diluted earnings per share	-$1.13+29.8%	-$1.61+19.9%	-$2.01+13.4%	-$2.32+14.7%	-$2.72+12.0%
Basic earnings per share	-$1.13+29.8%	-$1.61+19.9%	-$2.01+13.4%	-$2.32+14.7%	-$2.72+12.0%
Weighted-average shares, diluted	169.7M+2.2%	166.1M+2.6%	161.9M+2.7%	157.7M+3.0%	153.2M+2.7%
Weighted-average shares, basic	169.7M+2.2%	166.1M+2.6%	161.9M+2.7%	157.7M+3.0%	153.2M+2.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent	-$48.65M+26.5%	-$66.22M+18.5%	-$81.22M+11.5%	-$91.78M+12.4%	-$104.8M+9.2%
Interest Income, Other	$16.02M+1.7%	$15.75M+2.0%	$15.44M0.0%	$15.45M+0.6%	$15.35M+2.2%
Unrealized gains (losses) on available-for-sale securities	-$383K-290%	$202K—	——	——	——
Other income, net (Note 6)	-$208K-3.0%	-$202K-30.3%	-$155K+16.7%	-$186K-75.5%	-$106K+48.5%
EBIT	-$50.81M+28.4%	-$70.97M+18.8%	-$87.41M+10.8%	-$98.05M+10.2%	-$109.17M+9.5%
EBITDA	-$49.13M+29.1%	-$69.27M+19.2%	-$85.72M+11.1%	-$96.46M+10.5%	-$107.77M+9.7%
EBITDA	-$49.13M+29.1%	-$69.27M+19.2%	-$85.72M+11.1%	-$96.46M+10.5%	-$107.77M+9.7%
EBITDA margin	-9.2%+6.2pp	-15.3%+8.1pp	-23.4%+9.2pp	-32.6%+13.5pp	-46.1%+19.1pp
EBIT	-$50.81M+28.4%	-$70.97M+18.8%	-$87.41M+10.8%	-$98.05M+10.2%	-$109.17M+9.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Tarsus Pharmaceuticals, Inc.'s income statement data come from?: Every line is extracted from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.